We are grateful to U.S. taxpayers for the following research awards:

  • National Institute of General Medical Sciences, STTR Phase I. Cold-Sensitive Mutants of Taq DNA Polymerase 4/1/00 - 9/30/01 $154,502
  • National Institute of General Medical Sciences, SBIR Phase I. Toward a Heat-Labile Chelator for Hot-Start PCR 5/1/01 10/31/02 $107,856
  • National Institute of General Medical Sciences, SBIR Phase II. Cold-Sensitive Mutants of Taq DNA Polymerase 8/1/02 - 7/31/05 $689,155
  • National Institute of General Medical Sciences, SBIR Phase I. Reversible Magnesium Precipitation for Hot-Start PCR 8/1/02 - 1/31/04 $100,000
  • National Institute of General Medical Sciences, SBIR Phase I. Blood Inhibition Resistant Mutants of Taq DNA Polymerase 3/8/05 - 3/6/06 $107,144
  • United States Department of Agriculture, SBIR Phase I. Soil Inhibition Resistant Mutants of Taq DNA Polymerase 5/1/05 - 6/30/06 $78,160
  • National Institute of General Medical Sciences, SBIR Phase II. Blood Inhibition Resistant Mutants of Taq DNA Polymerase 3/7/06 - 3/6/08 $678,280
  • United States Department of Agriculture, SBIR Phase II. Soil Inhibition Resistant Mutants of Taq DNA Polymerase 9/15/06 - 9/14/08 $290,400
  • United States Department of Justice, Cooperative Agreement. Taq Mutants Engineered for Forensics, 1/1/2009 - 12/31/2010 $200,621
  • National Science Foundation, SBIR Phase I. Inhibition-Resistant DNA Polymerases and Other Improvements for Detection of Food-borne Pathogens 1/1/2010 - 12/31/2010 $142,505
  • National Institute of General Medical Sciences, SBIR Phase I. Direct RT-PCR detection of RNA pathogens and mRNA expression in crude samples. 8/1/2010 - 1/31/2012 $105,905
  • National Science Foundation, SBIR Phase II. Inhibition-Resistant DNA Polymerases and Other Improvements for Detection of Food-borne Pathogens. 9/15/2011 - 8/31/2013 $500,000
  • National Institute of General Medical Sciences, SBIR Phase II. Direct RT-PCR detection of RNA pathogens in crude samples. 7/1/2014-6/30/2018 $898,896
  • National Institute of General Medical Sciences, SBIR Phase I. Robust and Fast Taq Mutants Designed for Direct and Rapid Point of Care Tests. 9/15/2018 - 9/14/2020 $149,711